Enliven Therapeutics (ELVN) Return on Capital Employed (2020 - 2026)
Enliven Therapeutics (ELVN) posted Return on Capital Employed of 25.22% for Q1 2026, up 1.56% sequentially from 25.63% in Q4 2025, and up 1150.0% YoY from 2.02% in Q1 2025.
Enliven Therapeutics (ELVN) Return on Capital Employed (2020 - 2026) Analysis & Trends
Enliven Therapeutics has reported Return on Capital Employed for 7 years, with the latest figure at 25.22% in Q1 2026.
- Quarterly Return on Capital Employed rose 1150.0% year-over-year to 25.22% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 25.22% (up 1150.0% YoY) and the FY2025 annual result came in at 31.13%, up 583.0% from the prior year.
- Return on Capital Employed climbed to 25.22% in Q1 2026 per ELVN's latest filing, from 25.63% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 20.12% in Q2 2023 and troughed at 71.52% in Q3 2022.
- A 5-year average of 37.69% and a median of 32.98% in 2024 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2022 and 2023: Return on Capital Employed slumped 1259 bps in 2022, then surged 4530 bps in 2023.
- Over 5 years, Return on Capital Employed stood at 63.09% in 2022, then surged by 46 bps to 33.81% in 2023, then declined by 3 bps to 34.89% in 2024, then increased by 27 bps to 25.63% in 2025, then advanced by 2 bps to 25.22% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 25.22%, 25.63%, and 23.26% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Enliven Therapeutics | 4.31 Bn | 3.41 Bn | - | -18.48% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -18.48% |
| Mar 31, 2026 | -25.22% |
| Dec 31, 2025 | -25.63% |
| Sep 30, 2025 | -23.26% |
| Jun 30, 2025 | -29.44% |
| Mar 31, 2025 | -36.73% |
| Dec 31, 2024 | -34.89% |
| Sep 30, 2024 | -33.55% |
| Jun 30, 2024 | -31.19% |
| Mar 31, 2024 | -32.98% |
| Dec 31, 2023 | -33.81% |
| Sep 30, 2023 | -26.36% |
| Jun 30, 2023 | -20.12% |
| Mar 31, 2023 | -25.55% |
| Dec 31, 2022 | -63.09% |
| Sep 30, 2022 | -71.52% |
| Jun 30, 2022 | -65.42% |
| Mar 31, 2022 | -61.99% |
| Dec 31, 2021 | -55.24% |
| Sep 30, 2021 | -58.94% |